As lawyers who represent whistleblowers under the False Claims Act, we expect a new era of fraud cases tied to GLP-1 drugs, ...

Medicare is expanding its drug price negotiation program to include 15 more medications, including popular drugs like Ozempic ...

The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

If the plan pans out, it would be an enormous boon to Eli Lilly and Novo Nordisk. Currently, many health insurance plans, as ...

The new model incorporates artificial intelligence to help make decisions and is being tested in six states beginning in ...

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...

For 14 years, Jesse’s mind spiraled. So did his weight. The medications he took for schizophrenia drove his weight up until ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

CMS often withholds coverage for reimbursement, disrupting the natural flow of the market and hindering access to proven ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...